IL316894A - Anti-tnfr2 antibodies and methods of use thereof - Google Patents
Anti-tnfr2 antibodies and methods of use thereofInfo
- Publication number
- IL316894A IL316894A IL316894A IL31689424A IL316894A IL 316894 A IL316894 A IL 316894A IL 316894 A IL316894 A IL 316894A IL 31689424 A IL31689424 A IL 31689424A IL 316894 A IL316894 A IL 316894A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- tnfr2 antibodies
- tnfr2
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263365371P | 2022-05-26 | 2022-05-26 | |
| US202363499860P | 2023-05-03 | 2023-05-03 | |
| PCT/IB2023/055300 WO2023228082A1 (en) | 2022-05-26 | 2023-05-23 | Anti-tnfr2 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316894A true IL316894A (en) | 2025-01-01 |
Family
ID=86776418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316894A IL316894A (en) | 2022-05-26 | 2023-05-23 | Anti-tnfr2 antibodies and methods of use thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230406951A1 (en) |
| EP (1) | EP4532546A1 (en) |
| JP (1) | JP2025517490A (en) |
| KR (1) | KR20250017237A (en) |
| CN (1) | CN120380017A (en) |
| AU (1) | AU2023276940A1 (en) |
| CA (1) | CA3256751A1 (en) |
| CO (1) | CO2024015993A2 (en) |
| IL (1) | IL316894A (en) |
| MX (1) | MX2024014579A (en) |
| PE (1) | PE20250164A1 (en) |
| TW (1) | TW202402789A (en) |
| WO (1) | WO2023228082A1 (en) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5624A (en) | 1848-06-13 | Fastening foe | ||
| US821A (en) | 1838-06-30 | blake | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP2002522063A (en) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | Generation of modified molecules with increased serum half-life |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2006113546A2 (en) | 2005-04-15 | 2006-10-26 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| CA2676529C (en) | 2007-01-24 | 2014-03-25 | Kyowa Kirin Co., Ltd. | Genetically recombinant antibody composition having enhanced effector activity |
| EP3494139B1 (en) * | 2016-08-05 | 2022-01-12 | F. Hoffmann-La Roche AG | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| KR20210087466A (en) * | 2018-11-01 | 2021-07-12 | 바이오인벤트 인터내셔날 에이비 | Novel agonistic anti-TNFR2 antibody molecule |
| EP3880711A4 (en) * | 2018-11-15 | 2022-12-28 | The General Hospital Corporation | AGONIST POLYPEPTIDES OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY |
| JP2024527576A (en) * | 2021-07-07 | 2024-07-25 | ハイファイバイオ(ホンコン)リミテッド | Anti-TNFR2 antibodies and uses thereof |
-
2023
- 2023-05-23 IL IL316894A patent/IL316894A/en unknown
- 2023-05-23 JP JP2024569374A patent/JP2025517490A/en active Pending
- 2023-05-23 CN CN202380050294.6A patent/CN120380017A/en active Pending
- 2023-05-23 PE PE2024002700A patent/PE20250164A1/en unknown
- 2023-05-23 WO PCT/IB2023/055300 patent/WO2023228082A1/en not_active Ceased
- 2023-05-23 AU AU2023276940A patent/AU2023276940A1/en active Pending
- 2023-05-23 CA CA3256751A patent/CA3256751A1/en active Pending
- 2023-05-23 EP EP23731370.5A patent/EP4532546A1/en active Pending
- 2023-05-23 KR KR1020247042719A patent/KR20250017237A/en active Pending
- 2023-05-25 US US18/323,629 patent/US20230406951A1/en active Pending
- 2023-05-25 TW TW112119435A patent/TW202402789A/en unknown
-
2024
- 2024-11-25 MX MX2024014579A patent/MX2024014579A/en unknown
- 2024-11-25 CO CONC2024/0015993A patent/CO2024015993A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2024015993A2 (en) | 2024-12-09 |
| KR20250017237A (en) | 2025-02-04 |
| JP2025517490A (en) | 2025-06-05 |
| PE20250164A1 (en) | 2025-01-22 |
| EP4532546A1 (en) | 2025-04-09 |
| US20230406951A1 (en) | 2023-12-21 |
| CN120380017A (en) | 2025-07-25 |
| WO2023228082A1 (en) | 2023-11-30 |
| MX2024014579A (en) | 2025-01-09 |
| CA3256751A1 (en) | 2023-11-30 |
| TW202402789A (en) | 2024-01-16 |
| AU2023276940A1 (en) | 2024-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB202019709D0 (en) | Anti-Coronavirus antibodies and methods of use | |
| IL316368A (en) | Anti-tl1a antibodies and methods of use thereof | |
| HUE070287T2 (en) | Anti-par-2 antibodies and methods of use thereof | |
| IL315845A (en) | Anti-dectin-1 antibodies and methods of use thereof | |
| EP4089115A4 (en) | ANTI-TIGIT ANTIBODIES AND METHOD OF USE | |
| IL298668B1 (en) | Anti-cd200r1 antibodies and methods of use thereof | |
| IL319590A (en) | Multispecific antibodies and methods of use thereof | |
| IL316065A (en) | Anti-cd28 antibodies and methods of use thereof | |
| IL317690A (en) | Anti-gpnmb antibodies and methods of use thereof | |
| IL318694A (en) | Anti-ccr8 antibodies and methods of use | |
| IL308260A (en) | Anti-tigit antibodies and methods of use thereof | |
| IL316700A (en) | Anti-bmp9 antibodies and methods of use thereof | |
| IL311003A (en) | Anti-her2 antibodies and methods of use thereof | |
| IL325937A (en) | AAV-delivered antibodies and methods of using them | |
| IL318357A (en) | Anti- il27r antibodies and methods of use thereof | |
| IL321679A (en) | Anti-ror-2 antibodies and methods of use | |
| IL310551A (en) | Osmr-specific monoclonal antibodies and methods of their use | |
| AU2024374796A1 (en) | Anti-migis-alpha antibodies and methods of use thereof | |
| IL325840A (en) | Bispecific PD-L1XCD28 antibodies and methods of using them | |
| IL325837A (en) | Bispecific PD-L1X4-1BB antibodies and methods of using them | |
| GB202204813D0 (en) | Human monoclonal antibodies and methods of use thereof | |
| GB202204736D0 (en) | Human monoclonal antibodies and methods of use thereof | |
| CA3303930A1 (en) | Anti-nectin-4 antibodies and methods of use thereof | |
| CA3298139A1 (en) | Aav-delivered antibodies and methods of use thereof | |
| CA3292076A1 (en) | Anti-toh1 antibodies and methods of use thereof |